Stephens Investment Management Group LLC Buys 61,120 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Stephens Investment Management Group LLC lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.5% during the fourth quarter, Holdings Channel reports. The fund owned 1,406,522 shares of the specialty pharmaceutical company’s stock after acquiring an additional 61,120 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Supernus Pharmaceuticals were worth $69,904,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Hantz Financial Services Inc. raised its stake in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares in the last quarter. Torren Management LLC bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $49,000. Smartleaf Asset Management LLC raised its stake in shares of Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 268 shares in the last quarter. Vestcor Inc bought a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at approximately $67,000. Finally, State of Wyoming bought a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at approximately $68,000.

Supernus Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ:SUPN opened at $49.43 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $30.83 and a 1-year high of $59.68. The firm has a market capitalization of $2.87 billion, a PE ratio of -96.92, a PEG ratio of 1.07 and a beta of 0.57. The business’s 50 day moving average is $50.53 and its 200-day moving average is $49.90.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 7,250 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total transaction of $359,600.00. Following the sale, the vice president owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This trade represents a 29.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Georges Gemayel sold 8,787 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $53.00, for a total value of $465,711.00. Following the sale, the director directly owned 27,277 shares in the company, valued at $1,445,681. The trade was a 24.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 120,881 shares of company stock worth $6,139,356 in the last three months. Company insiders own 8.80% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.